Skip to main content
Equibles
PTGX logo

PTGX · Protagonist Therapeutics, Inc · Metrics

Track PTGX — free

Use PTGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$138.43 -1.10 (-0.79%) At close · Oct 23
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.96B
Shares
64.71M
Volume · Oct 23 409.36K Avg daily vol (3M) 635.32K

PTGX metrics

85 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$138.43
Market cap
$8.96B

Price action

20 metrics
Price change (1W)
+7.5%
Price change (30D)
-2.4%
Price change (3M)
+1.7%
Price change (6M)
+38.4%
Price change (YTD)
+58.5%
Price change (1Y)
+87.1%
Trailing year
Price change (5Y)
+347.1%
52-week high
$158.62
52-week low
$73.99
Change from 52-week high
-12.7%
Change from 52-week low
+87.1%
Annualized volatility
40.1%
Annualized volatility (3M)
35.2%
Beta
0.9
RSI (14D)
47.9
Price vs SMA 50
-4.0%
Price vs SMA 200
+20.3%
Avg volume (3M)
635,319
Relative volume
0.6
Average dollar volume
$90.76M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.71M

Valuation

12 metrics
P / E (TTM)
134.4
Trailing earnings · reciprocal yield 0.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
31.8×
reciprocal yield 3.1%
P / book
10.6
reciprocal yield 9.4%
FCF yield
1.5%
TTM · current market cap
Buyback yield
—
P / FCF
68.6
reciprocal yield 1.5%
P / operating cash flow
68.3
reciprocal yield 1.5%
Earnings yield
0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
78.6×
reciprocal yield 1.3%
P / E historical average (5Y)
78.6×
reciprocal yield 1.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
20.7%
Trailing 12 months
Net margin
29.4%
Gross profit (TTM)
—
Operating profit (TTM)
$58.34M
Net income (TTM)
$82.91M
Trailing 12 months
Diluted EPS (TTM)
$1.03
FCF margin
46.3%
Effective tax rate
1.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$4.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$0.67
EBITDA per diluted share (TTM)
$0.69
Net income per diluted share (TTM)
$1.04
Operating cash flow per diluted share (TTM)
$1.78
Free cash flow per diluted share (TTM)
$1.77
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$2.61
Stock compensation per diluted share (TTM)
$0.74
Book value per share
$9.82

Growth

11 metrics
Revenue growth YoY
+3,749.2%
Year over year
Net income growth YoY
-147.3%
Revenue (TTM)
$281.99M
Trailing 12 months
EPS growth YoY
-148.5%
Shares change YoY
+11.8%
Year over year · more shares
Revenue CAGR (3Y)
+20.1%
Revenue CAGR (5Y)
+10.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
9.9%
Return on assets
9.4%
Debt / equity
—
Current ratio
21.7
EBITDA (TTM)
$59.88M
Free cash flow (TTM)
$130.58M
Quick ratio
21.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$420.08M
Total assets
$885.54M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$131.20M
Capital expenditures (TTM)
$615,000
R&D (TTM)
$175.16M
SG&A (TTM)
—
Stock compensation (TTM)
$49.82M
R&D / revenue
62.1%
Stock compensation / revenue
17.7%

Ownership (13F)

9 metrics
13F filers
346
13F filer change QoQ
+21
Institutional ownership
118.1%
Conviction holders (share of 13F filers)
2.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-7.0%
Holder tenure
14.7
Price vs estimated holder cost
+85.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
29.6%

Short interest

3 metrics
Short interest
14.4%
Latest settlement · 11.5 days to cover
Days to cover
11.5d
Short-squeeze score
79 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$41.44M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1377121 CUSIP 74366E102 13F (30d) 56 filings 56 filers Visit website Investor relations